2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Unknown
12
Completed
8
Recruiting
5
Terminated
2
Active not recruiting
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Breast Neoplasms
1131
Neoplasms
986
Carcinoma, Non-Small-Cell Lung
903
Prostatic Neoplasms
595
Neoplasm Metastasis
529
Leukemia, Myeloid, Acute
514
Colorectal Neoplasms
492
Lung Neoplasms
490
Melanoma
488
Multiple Myeloma
478
Pancreatic Neoplasms
387
Lymphoma
370
Ovarian Neoplasms
368
Recurrence
365
Lymphoma, Non-Hodgkin
348
Leukemia
340
Leukemia, Lymphocytic, Chronic, B-Cell
322
Precursor Cell Lymphoblastic Leukemia-Lymphoma
291
Head and Neck Neoplasms
276
Carcinoma, Renal Cell
276
Brain Neoplasms
276
Carcinoma, Hepatocellular
261
Glioblastoma
250
Myelodysplastic Syndromes
244
Lymphoma, Large B-Cell, Diffuse
244
Squamous Cell Carcinoma of Head and Neck
241
Lymphoma, Follicular
236
Colonic Neoplasms
214
Stomach Neoplasms
200
Rectal Neoplasms
190
Interventions
donafenib
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Differentiated Thyroid Cancer
×
Clear all
NCT03602495
2021-12-13
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Terminated
204 enrolled
NCT01843062
2019-08-28
ASTRA
AstraZeneca
Phase 3
Terminated
233 enrolled
14 charts